RE:RE:RE:RE:RE:PPI don't think the poor response to the second pp had anything to do with how TLT treats its investors. The pp was a great deal. There simply aren't enough wealthy investors involved in TLT to take advantage of the deal. The science behind the therapy is brilliant. I suspect some tweeking after FDA approval will increase results even further. GLTA.